Cargando…
TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models
The ruthenium-based photosensitizer (PS) TLD1433 has completed a phase I clinical trial for photodynamic therapy (PDT) treatment of bladder cancer. Here, we investigated a possible repurposing of this drug for treatment of conjunctival melanoma (CM). CM is a rare but often deadly ocular cancer. The...
Autores principales: | Chen, Quanchi, Ramu, Vadde, Aydar, Yasmin, Groenewoud, Arwin, Zhou, Xue-Quan, Jager, Martine J., Cole, Houston, Cameron, Colin G., McFarland, Sherri A., Bonnet, Sylvestre, Snaar-Jagalska, B. Ewa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139549/ https://www.ncbi.nlm.nih.gov/pubmed/32143295 http://dx.doi.org/10.3390/cancers12030587 |
Ejemplares similares
-
Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model
por: Chen, Quanchi, et al.
Publicado: (2022) -
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
por: Chamberlain, Sarah, et al.
Publicado: (2020) -
Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target
por: Cao, Jinfeng, et al.
Publicado: (2018) -
Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
por: Glinkina, Kseniya, et al.
Publicado: (2022) -
The
Self-Assembly of a Cyclometalated Palladium Photosensitizer
into Protein-Stabilized Nanorods Triggers Drug Uptake In Vitro and
In Vivo
por: Zhou, Xue-Quan, et al.
Publicado: (2020)